132 related articles for article (PubMed ID: 35377864)
21. Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer.
Cunningham-Bussel A; Wang J; Prisco LC; Martin LW; Vanni KMM; Zaccardelli A; Nasrallah M; Gedmintas L; MacFarlane LA; Shadick NA; Awad MM; Rahma O; LeBoeuf NR; Gravallese EM; Sparks JA
Arthritis Rheumatol; 2022 Mar; 74(3):527-540. PubMed ID: 34397169
[TBL] [Abstract][Full Text] [Related]
22. Prognosis of immune checkpoint inhibitors-induced myocarditis: a case series.
Coustal C; Vanoverschelde J; Quantin X; Lesage C; Michot JM; Lappara A; Ederhy S; Assenat E; Faure M; Issa N; Lambotte O; Puyade M; Dereure O; Tosi D; Rullier P; Serre I; Larcher R; Klouche K; Chanques G; Vernhet-Kovacsik H; Faillie JL; Agullo A; Roubille F; Guilpain P; Maria ATJ
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37258037
[TBL] [Abstract][Full Text] [Related]
23. Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis.
Grouthier V; Lebrun-Vignes B; Moey M; Johnson DB; Moslehi JJ; Salem JE; Bachelot A
Oncologist; 2020 Aug; 25(8):696-701. PubMed ID: 32390168
[TBL] [Abstract][Full Text] [Related]
24. A retrospective chart review of management strategies for lichenoid eruptions associated with immune-checkpoint inhibitor therapy from a single institution.
Masterson WM; Brown AM; Al Ameri MA; Patel AB
Cancer Treat Res Commun; 2022; 30():100506. PubMed ID: 34990901
[TBL] [Abstract][Full Text] [Related]
25. Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report.
Hultin S; Nahar K; Menzies AM; Long GV; Fernando SL; Atkinson V; Cebon J; Wong MG
BMC Nephrol; 2020 Sep; 21(1):391. PubMed ID: 32894101
[TBL] [Abstract][Full Text] [Related]
26. Immune-Related Adverse Events After Immune Checkpoint Inhibitors for Melanoma Among Older Adults.
Schonfeld SJ; Tucker MA; Engels EA; Dores GM; Sampson JN; Shiels MS; Chanock SJ; Morton LM
JAMA Netw Open; 2022 Mar; 5(3):e223461. PubMed ID: 35315916
[TBL] [Abstract][Full Text] [Related]
27. Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance.
Bhardwaj M; Chiu MN; Pilkhwal Sah S
Cutan Ocul Toxicol; 2022 Mar; 41(1):73-90. PubMed ID: 35107396
[TBL] [Abstract][Full Text] [Related]
28. Type 1 diabetes associated with immune checkpoint inhibitors for malignant melanoma: A case report and review of 8 cases.
Ishiguro A; Ogata D; Ohashi K; Hiki K; Yamakawa K; Jinnai S; Tsutsui K; Takahashi A; Namikawa K; Yamazaki N
Medicine (Baltimore); 2022 Sep; 101(35):e30398. PubMed ID: 36107581
[TBL] [Abstract][Full Text] [Related]
29. Cutaneous Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors and Their Management.
Pach J; Leventhal JS
Crit Rev Immunol; 2022; 42(4):1-20. PubMed ID: 37022356
[TBL] [Abstract][Full Text] [Related]
30. [Blistering drug reactions].
Roujeau JC
Rev Prat; 2000 Jun; 50(12):1320-3. PubMed ID: 10972073
[TBL] [Abstract][Full Text] [Related]
31. Lichenoid dermatitis from immune checkpoint inhibitor therapy: An immune-related adverse event with mycosis-fungoides-like morphologic and molecular features.
Tetzlaff MT; Tang S; Duke T; Grabell DA; Cabanillas ME; Zuo Z; Yao JC; Nagarajan P; Aung PP; Torres-Cabala CA; Duvic M; Prieto VG; Huen A; Curry JL
J Cutan Pathol; 2019 Nov; 46(11):872-877. PubMed ID: 31254410
[TBL] [Abstract][Full Text] [Related]
32. Cutaneous lichenoid drug eruptions: A narrative review evaluating demographics, clinical features and culprit medications.
Maul JT; Guillet C; Oschmann A; Maul LV; Meier-Schiesser B; Stadler PC; French LE; Kerl K
J Eur Acad Dermatol Venereol; 2023 May; 37(5):965-975. PubMed ID: 36652271
[TBL] [Abstract][Full Text] [Related]
33. Oral mucosal toxicities induced by immune checkpoint inhibitors: Clinical features and algorithm management.
Vigarios E; Sibaud V
Ann Dermatol Venereol; 2023 Jun; 150(2):83-88. PubMed ID: 36935341
[TBL] [Abstract][Full Text] [Related]
34. Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition - A Descriptive Observational Retrospective Multicenter Analysis.
Zaremba A; Kramer R; De Temple V; Bertram S; Salzmann M; Gesierich A; Reinhardt L; Baroudjian B; Sachse MM; Mechtersheimer G; Johnson DB; Weppler AM; Spain L; Loquai C; Dudda M; Pföhler C; Hepner A; Long GV; Menzies AM; Carlino MS; Lebbé C; Enokida T; Tahara M; Bröckelmann PJ; Eigentler T; Kähler KC; Gutzmer R; Berking C; Ugurel S; Stadtler N; Sucker A; Becker JC; Livingstone E; Meier F; Hassel JC; Schadendorf D; Hanoun M; Heinzerling L; Zimmer L
Front Oncol; 2021; 11():765608. PubMed ID: 34746007
[TBL] [Abstract][Full Text] [Related]
35. Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management.
Amber KT; Murrell DF; Schmidt E; Joly P; Borradori L
Clin Rev Allergy Immunol; 2018 Feb; 54(1):26-51. PubMed ID: 28779299
[TBL] [Abstract][Full Text] [Related]
36. Cutaneous adverse events caused by immune checkpoint inhibitors.
Quach HT; Johnson DB; LeBoeuf NR; Zwerner JP; Dewan AK
J Am Acad Dermatol; 2021 Oct; 85(4):956-966. PubMed ID: 34332798
[TBL] [Abstract][Full Text] [Related]
37. Toxic epidermal necrolysis occurring with immune checkpoint inhibitors.
Gopee NH; Gourley AM; Oliphant TJ; Hampton PJ
Dermatol Online J; 2020 Aug; 26(8):. PubMed ID: 32941713
[TBL] [Abstract][Full Text] [Related]
38. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
39. Population-Based Frequency of Ophthalmic Adverse Events in Melanoma, Other Cancers, and After Immune Checkpoint Inhibitor Treatment.
Braun D; Getahun D; Chiu VY; Coleman AL; Holland GN; Yu F; Gordon LK; Sun MM
Am J Ophthalmol; 2021 Apr; 224():282-291. PubMed ID: 33359682
[TBL] [Abstract][Full Text] [Related]
40. Evolving spectrum of drug-induced uveitis at the era of immune checkpoint inhibitors results from the WHO's pharmacovigilance database.
Anquetil C; Salem JE; Lebrun-Vignes B; Touhami S; Desbois AC; Maalouf G; Domont F; Allenbach Y; Cacoub P; Bodaghi B; Saadoun D
J Autoimmun; 2020 Jul; 111():102454. PubMed ID: 32303423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
